Cancer Research UK is recruiting patients for a PHASE1/PHASE2 clinical trial testing atezolizumab (Tecentriq) for mesothelioma.
The trial, designated NCT05944237, aims to enroll up to 150 participants at 5 sites.
About the Study
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.
Treatment Approach
This trial uses a PD-L1 checkpoint inhibitor being studied in combination with other treatments.
Key trial details:
- Phase: PHASE1/PHASE2
- Sponsor: Cancer Research UK
- Enrollment target: 150
- Status: RECRUITING
Why This Trial Matters
Study Locations
Contact the trial sponsor for information about participating sites.
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening